Specialized compound could lead to chronic pain relief without the use of opioids

March 14, 2017 by Curt Slyder, Purdue University
Credit: CC0 Public Domain

Purdue researchers have discovered a compound that could lead to the treatment of chronic pain without the need for patients to rely on opioids.

A team led by Val Watts, associate head and professor of medicinal chemistry and molecular pharmacology in Purdue's College of Pharmacy, said the compound shows unparalleled selectivity in inhibiting the 1 (AC1).

Adenylyl cyclases are enzymes that organize the production of cyclic adenosine monophosphate, an important biological messenger in numerous organisms. There are 10 isoforms of adenylyl cyclases found in humans. Numerous studies have suggested that AC1 could be used as a drug target for .

The compound identified at Purdue has shown selectivity for inhibiting AC1 versus the other nine isoforms.

"With the AC1 technology, there's a chance to treat chronic pain directly or through reducing the side effects of the opioids," said team member Richard van Rijn, assistant professor of and in Purdue's College of Pharmacy. "There's an issue with misuse of opioids used to treat chronic pain. They are good as a short-term analgesic for , but don't address the underlying issues of chronic pain."

Opioids are a class of drugs that include the illicit drug heroin as well as oxycodone, hydrocodone, codeine, morphine, fentanyl and others. They interact with opioid receptors on nerve cells in the brain and nervous system to produce pleasurable effects and relieve pain.

According to the Centers for Disease Control and Prevention, overdose deaths involving have quadrupled since 1999. From 1999 to 2015, more than 183,000 people have died in the United States from overdoses related to prescription opioids.

The Watts group is the first to identify a compound that is selective for AC1 only.

Findings from the study are published in a research paper by Watts' group that recently appeared in Science Signaling. There is also a recent news feature about the research in Science.

While the research is still in its early stages, another potential application for the compound is the possibility of reducing opioid dependence. Separate research has shown that completely deleting the AC1 enzyme reduces the signs of dependence.

"If you decrease the physical symptoms of withdrawal, that could help reduce psychological dependence," Watts said. "You might also be able to stop relapse."

Explore further: Physical therapy is best choice for pain management

More information: Tarsis F. Brust et al. Identification of a selective small-molecule inhibitor of type 1 adenylyl cyclase activity with analgesic properties, Science Signaling (2017). DOI: 10.1126/scisignal.aah5381

Related Stories

Physical therapy is best choice for pain management

August 29, 2016
According to the Centers for Disease Control and Prevention (CDC), sales of prescription opioids have quadrupled in the United States since 1999, even though there has not been an overall change in the amount of pain reported.

Key signaling protein associated with addiction controls the actions of oxycodone on pain

January 17, 2017
RGS9-2, a key signaling protein in the brain known to play a critical role in the development of addiction-related behaviors, acts as a positive modulator of oxycodone reward in both pain-free and chronic pain states, according ...

DEA puts quota on production of opioid painkillers

October 6, 2016
(HealthDay)—The U.S. Drug Enforcement Administration (DEA) says it has mandated significant cuts in the production of powerful prescription opioid painkillers.

Opioids produce analgesia via immune cells

January 17, 2017
Opioids are the most powerful painkillers. Researchers at the Charité - Universitätsmedizin Berlin have now found that the analgesic effects of opioids are not exclusively mediated by opioid receptors in the brain, but ...

Despite opioid concerns, seniors often exit the hospital with prescription, study says

July 19, 2016
It's a common scenario: Someone checks into a hospital for surgery or an illness and leaves with a prescription for an opioid painkiller, opening the door to long-term use and dependence. A recent study examined this pattern ...

Recommended for you

Study: Ibuprofen, acetaminophen more effective than opioids in treating dental pain

April 17, 2018
Opioids are not among the most effective—or longest lasting—options available for relief from acute dental pain, a new examination of the results from more than 460 published studies has found.

Text messaging tool may help fight opioid epidemic

April 17, 2018
A new automated text messaging service may curb opioid abuse and reduce the likelihood of relapse while also decreasing treatment costs, according to researchers at Washington University School of Medicine and Epharmix, a ...

Marijuana-based drug gets positive review from US agency

April 17, 2018
A closely watched medicine made from the marijuana plant reduces seizures in children with severe forms of epilepsy and warrants approval in the United States, health officials said Tuesday.

Post-surgical opioids can, paradoxically, lead to chronic pain

April 16, 2018
Giving opioids to animals to quell pain after surgery prolongs pain for more than three weeks and primes specialized immune cells in the spinal cord to be more reactive to pain, according to a new study by the University ...

Animal study suggests common diabetes drug may also help with nicotine withdrawal

April 5, 2018
In a mouse study, a drug that has helped millions of people around the world manage their diabetes might also help people ready to kick their nicotine habits.

20 years after Viagra, Pfizer seeks another miracle drug

April 1, 2018
It has been 20 years since Viagra was introduced, and Pfizer is still searching for another drug with as much earning power as the revolutionary blue erection pill.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.